Ingalls & Snyder LLC’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.75M Buy
78,370
+148
+0.2% +$8.63K 0.17% 102
2025
Q4
$4.22M Sell
78,222
-33,848
-30% -$1.63M 0.15% 104
2025
Q3
$5.05M Sell
112,070
-7,696
-6% -$359K 0.17% 92
2025
Q2
$5.54M Sell
119,766
-7,085
-6% -$348K 0.2% 82
2025
Q1
$7.74M Sell
126,851
-5,826
-4% -$340K 0.25% 63
2024
Q4
$7.5M Sell
132,677
-29,154
-18% -$1.63M 0.29% 64
2024
Q3
$8.37M Sell
161,831
-31,505
-16% -$1.48M 0.33% 58
2024
Q2
$8.03M Sell
193,336
-274,803
-59% -$12.3M 0.35% 54
2024
Q1
$25.4M Buy
468,139
+36,072
+8% +$1.84M 1.12% 19
2023
Q4
$22.2M Sell
432,067
-51,879
-11% -$2.72M 1% 23
2023
Q3
$28.1M Sell
483,946
-5,105
-1% -$313K 1.35% 14
2023
Q2
$31.3M Buy
489,051
+10,398
+2% +$697K 1.5% 13
2023
Q1
$33.2M Buy
478,653
+17,032
+4% +$1.2M 1.7% 10
2022
Q4
$33.2M Sell
461,621
-9,474
-2% -$714K 1.81% 9
2022
Q3
$33.5M Sell
471,095
-1,773
-0.4% -$129K 1.87% 9
2022
Q2
$36.4M Sell
472,868
-3,024
-0.6% -$230K 1.9% 9
2022
Q1
$34.8M Buy
475,892
+2,436
+0.5% +$164K 1.55% 11
2021
Q4
$29.5M Sell
473,456
-18,497
-4% -$1.09M 1.33% 14
2021
Q3
$29.1M Sell
491,953
-11,364
-2% -$748K 1.33% 15
2021
Q2
$33.6M Buy
503,317
+1,070
+0.2% +$69.8K 1.49% 13
2021
Q1
$31.7M Sell
502,247
-10,124
-2% -$630K 1.48% 12
2020
Q4
$31.8M Buy
+512,371
New +$31.5M 1.57% 13
2020
Q3
Sell
-509,601
Closed -$30M 392
2020
Q2
$30M Buy
509,601
+1,388
+0.3% +$83K 1.72% 9
2020
Q1
$28.3M Buy
508,213
+11,218
+2% +$686K 1.91% 8
2019
Q4
$31.9M Buy
496,995
+102,242
+26% +$5.86M 1.73% 11
2019
Q3
$20M Sell
394,753
-11,484
-3% -$540K 0.98% 24
2019
Q2
$18.4M Buy
406,237
+206,048
+103% +$9.6M 0.89% 27
2019
Q1
$9.55M Buy
200,189
+9,996
+5% +$498K 0.46% 59
2018
Q4
$9.89M Sell
190,193
-7,394
-4% -$397K 0.52% 49
2018
Q3
$12.3M Sell
197,587
-743
-0.4% -$44.1K 0.52% 52
2018
Q2
$11M Sell
198,330
-322
-0.2% -$17.4K 0.51% 53
2018
Q1
$12.6M Buy
198,652
+3,081
+2% +$198K 0.61% 42
2017
Q4
$12M Buy
195,571
+225
+0.1% +$14.1K 0.55% 48
2017
Q3
$12.5M Sell
195,346
-2,917
-1% -$170K 0.65% 40
2017
Q2
$11M Buy
198,263
+5,910
+3% +$322K 0.6% 42
2017
Q1
$10.5M Buy
192,353
+7,596
+4% +$417K 0.56% 45
2016
Q4
$10.8M Buy
184,757
+11,283
+7% +$617K 0.59% 43
2016
Q3
$9.35M Buy
173,474
+16,125
+10% +$1.04M 0.52% 45
2016
Q2
$11.6M Sell
157,349
-3,050
-2% -$216K 0.68% 38
2016
Q1
$10.2M Buy
160,399
+1,500
+0.9% +$94.6K 0.65% 41
2015
Q4
$10.9M Sell
158,899
-600
-0.4% -$39.6K 0.7% 38
2015
Q3
$9.44M Sell
159,499
-45
-0% -$2.85K 0.62% 42
2015
Q2
$10.6M Sell
159,544
-643
-0.4% -$42.4K 0.59% 40
2015
Q1
$10.3M Sell
160,187
-2,575
-2% -$161K 0.57% 39
2014
Q4
$9.61M Sell
162,762
-5,029
-3% -$284K 0.56% 40
2014
Q3
$8.59M Buy
167,791
+795
+0.5% +$39.7K 0.46% 50
2014
Q2
$8.1M Buy
166,996
+6,982
+4% +$344K 0.4% 53
2014
Q1
$8.31M Sell
160,014
-25
-0% -$1.33K 0.45% 49
2013
Q4
$8.51M Sell
160,039
-230
-0.1% -$11.7K 0.47% 50
2013
Q3
$7.42M Sell
160,269
-145
-0.1% -$6.37K 0.44% 49
2013
Q2
$7.17M Buy
+160,414
New +$6.96M 0.46% 50

Other funds holding BMY

Ingalls & Snyder LLC's BMY Position: Q1 2026 in Review

Ingalls & Snyder LLC increased its Bristol-Myers Squibb (BMY) stake by 0.19% in Q1 2026, buying an estimated $8.63K and bringing the position to 78,370 shares worth $4.75M. The position accounts for 0.17% of the portfolio, ranked #102.

Ingalls & Snyder LLC first reported a position in BMY in Q2 2013 and has held it in 51 quarters since. The position peaked at $36.4M in Q2 2022. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Ingalls & Snyder LLC held 78,370 shares of Bristol-Myers Squibb worth $4.75M as of Q1 2026.
  • Ingalls & Snyder LLC bought 148 Bristol-Myers Squibb shares in Q1 2026, an estimated $8.63K.
  • Bristol-Myers Squibb made up 0.17% of Ingalls & Snyder LLC's portfolio in Q1 2026, its #102 holding.
  • Ingalls & Snyder LLC first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 51 quarters since.
  • Ingalls & Snyder LLC's Bristol-Myers Squibb position peaked at $36.4M in Q2 2022.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Ingalls & Snyder LLC's 13F filing for Q1 2026, filed 13 May 2026.